Biotechnology company Arcellx has announced positive data from the Phase II study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM). 

Results from the iMMagine-1 study demonstrate deep and durable responses with a predictable and manageable safety profile in a fourth-line or higher (4L+) RRMM population, including triple- and penta-refractory disease. No delayed or non-ICANS neurotoxicities – including Parkinsonism, cranial nerve palsies, Guillain-Barré syndrome, and immune effector cell-associated enterocolitis – have been observed with anito-cel to date. 

All patients received a single infusion of anito-cel and a median of three prior lines of therapy. Overall response rate (ORR) was 96% with a complete response/stringent complete response (CR/sCR) rate of 74%.  

The results were presented at the American Society of Hematology (ASH) Annual Meeting and Exposition on 6 December. 

“These data are compelling and are an important advancement for patients living with multiple myeloma,” said Dr Krina Patel, Associate Professor at the Department of Lymphoma/Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, and iMMagine-1 and iMMagine-3 clinical investigator.  

“I am encouraged by the depth of responses in the iMMagine-1 study. For clinicians, we rely on therapies that deliver continued meaningful efficacy, a predictable safety profile, and reliable manufacturing. Anito-cel demonstrates that it could become a significant new treatment option in our efforts to improve outcomes for patients with multiple myeloma.” 

Bruno Quinney, Content Team, DDW